Evidence map›Paper›PMID 34567165›Full record

ArticleIranian journal of pharmaceutical research : IJPR2021

Inhibition of HMGB1 Might Enhance the Protective Effect of Taxifolin in Cardiomyocytes via PI3K/AKT Signaling Pathway.

Erjun Feng, Jian Wang, Xinwei Wang, Zhenguo Wang, Xiaochu Chen, Xu Zhu, Wenli Hou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Erjun FengDepartment of Cardiology, Fourth Center Hospital of Tianjin, Tianjin, China, 300000.
Jian WangDepartment of Cardiology, Fourth Center Hospital of Tianjin, Tianjin, China, 300000.
Xinwei WangOncology Department of Characteristic Medical Center of PAF, Tianjin, China, 300162.
Zhenguo WangMedical Research Department of Characteristic Medical Center of PAF, Tianjin, China, 300162.
Xiaochu ChenMedical Research Department of Characteristic Medical Center of PAF, Tianjin, China, 300162.
Xu ZhuSecond Department of Neurology, Central Hospital of Handan, Handan, China, 056000.
Wenli HouCadre Ward of Characteristic Medical Center of PAF, Tianjin, China, 300162.
Tianjin Medical University · CNZero to Three · USHandan College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVD) affect millions of people and spend a lot of medical costs around the world each year. Taxifolin is a natural anti-oxidative reagent obtained from multiple plants and exhibits a wide range of pharmacological effects. High mobility group box protein 1 (

Indexed as

CardiomyocytesHMGB1PI3K/AKT signaling pathwayTaxifolin

Identifiers

PMID34567165
PMCPMC8457741
OpenAlexW3186789551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.